|Synonyms||NCH 51; Cpd 51; S-[6-(4-Phenyl-2-thiazolylcarbamoyl)hexyl] thioisobutyrate|
|Purity Chemicals||≥95% (HPLC)|
|Solubility||Soluble in DMSO (25mg/ml).|
|Identity||Determined by NMR.|
|Declaration||Manufactured by Chemodex.|
|Other Product Data||
Click here for Original Manufacturer Product Datasheet
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||+4°C|
Keep cool and dry.
Protect from light and moisture.
|Use/Stability||Stable for at least 2 years after receipt when stored at +4°C.|
|Product Specification Sheet|
Non-hydroxamate HDAC inhibitor (HDACi) (IC50: 32, 48 and 41nM for HDAC4, HDAC1 and HDAC6, respectively). Cell-permeable prodrug that is intracellularly converted to a potent HDAC inhibitor. Predicted to exhibit a similar HDAC binding mode as that of SAHA, interacting with the active-site zinc targeting group. Shown to exhibit comparable antiproliferative and apoptotic activity as SAHA against various cancer cell lines. Inhibits growth of various cancer cells in vitro (EC50 = 1.1 - 9.1μM). Also reactivates latent HIV-1 gene expression.
(1) T. Suzuki, et al.; J. Med. Chem. 48, 1019 (2005) | (2) T. Sanda, et al.; Leukemia 21, 2344 (2007) | (3) T. Suzuki, et al.; Bioorg. Med. Chem. Lett. 17, 1558 (2007) | (4) A.F. Victoriano, et al.; FEBS Lett. 585, 1103 (2011)